4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions?
BackgroundImpaired functionality, cognitive decline, comorbidity and polypharmacy in nonagenarians increase mortality risks associated with age. Polypharmacy (>4 chronic drugs) in elderly people is related to an increase in drug-related problems (DRP) and worse health outcomes due to potentially...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A163-A163 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A163 |
---|---|
container_issue | Suppl 1 |
container_start_page | A163 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 25 |
creator | Roig, S Ortonobes Comas, G Puig Marzo, MA Villarino Monte, R Comet Albors, P Miralles Contel, A Perez Molas, G Gómez-Valent, M |
description | BackgroundImpaired functionality, cognitive decline, comorbidity and polypharmacy in nonagenarians increase mortality risks associated with age. Polypharmacy (>4 chronic drugs) in elderly people is related to an increase in drug-related problems (DRP) and worse health outcomes due to potentially inappropriate prescriptions (PIP). To optimise medical care for chronic patients, our healthcare system stratifies chronic patients according to their grade of chronicity in chronic complex patients (CCP) or CCP with advance chronic disease (CCP-ACD).PurposeTo evaluate the differences related to functionality, cognition, polypharmacy and pharmacist interventions due to DRP (PI-DRP) regarding the grade of chronicity.Material and methodsWe included ≥90 years-old patients with polypharmacy discharged between January and June of 2017 from an Acute Geriatric Unit (81 beds) of a Geriatric Healthcare Centre. Registered variables: age, sex, grade of chronicity, Barthel Index and Pfeiffer Test before admission. Number of chronic drug/patient, number of PIP/patient and chronic benzodiazepines use before admission, and PI-DRP. Data are presented as median (Q1–Q3). We use Fisher’s exact test for qualitative and the Mann–Whitney U test and the Wilcoxon signed-rank test for quantitative data. Statistical analysis was performed with Stata 13.ResultsOne hundred and eighteen patients included: 83 CCP and 35 CCP-ACD. Differences between CCP and CCP-ACD: age 92 (90–94) vs 94 (91–95), p=0.029. Females 58 (69.9%) vs 20 (57.1%), p=0.205. Data at admission: Barthel Index 55 (40–80) vs 40 (20–60), p=0.010; Pfeiffer Test three (1–6) vs four (2–8), p=0.432. Chronic drugs/patient 10 (8–12) vs 10 (7–14), p=0.972. Average of PIP/patient 1.2 (±0.88) vs 0.86 (±0.85), p=0.049; chronic benzodiazepines use 30 (36.1%) vs 6 (17.1%), p=0.050. PI-DRP: indication 10 (12%) vs 2 (5.7%) patients, p=0.506; effectivity 11 (13.3%) vs five (14.3), p=0.881; safety one (1.2%) vs four (11.4%), p=0.027; advice to nursing three (3.6%) vs two (5.7%), p=0.632; others 11 (13.3%) vs five (14.3%), p=0.881.ConclusionCCP–ACD group are older than CCP, and have worse results in functional status without differences in cognitive function.Although the number of chronic drugs prescribed between the two groups are similar, CCP–ACD have significantly less PIP and use less chronic benzodiazepines than CCP.The major pharmaceutical interventions have been those of safety in the CCP–ACD group.References and/or AcknowledgementsAll me |
doi_str_mv | 10.1136/ejhpharm-2018-eahpconf.351 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552768933</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2091-dd1ed5989d4260fd7e7619d317e4fb222e2ff3112c726b0f3aa5b29f056586993</originalsourceid><addsrcrecordid>eNqFkV9LwzAUxYsoOOa-Q9Dnzvxp0sYHRYZOYaCgPoe0SdaMNalpO9mbL35RP4md-wM--XQv3HPOPfCLonMExwgRdqkXZV3KUMUYoizWsqwL78yYUHQUDTBM0phzlhwfdspOo1HT2BxSQjKeED6ITDJ5fokxQ9-fX9MglQbegKIM3tnCtmtgHXDeybl2MljpmitQSAc-NCh8VcuggeuqXAcgnQLtuv61q9DNe2Orw0q71nrX3JxFJ0YuGz3azWH0dn_3OnmIZ0_Tx8ntLM4x5ChWCmlFecZVghk0KtUpQ1wRlOrE5BhjjY0hCOEixSyHhkhJc8wNpIxmjHMyjK63uXWXV1oV_f8gl6IOtpJhLby04u_F2VLM_UqklNCEkD7gYhcQ_Hunm1YsfBdc31lgSnHKMv6PCiJICMrQRkW3qrxaHCogKDbwxB7expCJPTzRwyM_BNOTZQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2010331813</pqid></control><display><type>article</type><title>4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions?</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Roig, S Ortonobes ; Comas, G Puig ; Marzo, MA Villarino ; Monte, R Comet ; Albors, P Miralles ; Contel, A Perez ; Molas, G ; Gómez-Valent, M</creator><creatorcontrib>Roig, S Ortonobes ; Comas, G Puig ; Marzo, MA Villarino ; Monte, R Comet ; Albors, P Miralles ; Contel, A Perez ; Molas, G ; Gómez-Valent, M</creatorcontrib><description>BackgroundImpaired functionality, cognitive decline, comorbidity and polypharmacy in nonagenarians increase mortality risks associated with age. Polypharmacy (>4 chronic drugs) in elderly people is related to an increase in drug-related problems (DRP) and worse health outcomes due to potentially inappropriate prescriptions (PIP). To optimise medical care for chronic patients, our healthcare system stratifies chronic patients according to their grade of chronicity in chronic complex patients (CCP) or CCP with advance chronic disease (CCP-ACD).PurposeTo evaluate the differences related to functionality, cognition, polypharmacy and pharmacist interventions due to DRP (PI-DRP) regarding the grade of chronicity.Material and methodsWe included ≥90 years-old patients with polypharmacy discharged between January and June of 2017 from an Acute Geriatric Unit (81 beds) of a Geriatric Healthcare Centre. Registered variables: age, sex, grade of chronicity, Barthel Index and Pfeiffer Test before admission. Number of chronic drug/patient, number of PIP/patient and chronic benzodiazepines use before admission, and PI-DRP. Data are presented as median (Q1–Q3). We use Fisher’s exact test for qualitative and the Mann–Whitney U test and the Wilcoxon signed-rank test for quantitative data. Statistical analysis was performed with Stata 13.ResultsOne hundred and eighteen patients included: 83 CCP and 35 CCP-ACD. Differences between CCP and CCP-ACD: age 92 (90–94) vs 94 (91–95), p=0.029. Females 58 (69.9%) vs 20 (57.1%), p=0.205. Data at admission: Barthel Index 55 (40–80) vs 40 (20–60), p=0.010; Pfeiffer Test three (1–6) vs four (2–8), p=0.432. Chronic drugs/patient 10 (8–12) vs 10 (7–14), p=0.972. Average of PIP/patient 1.2 (±0.88) vs 0.86 (±0.85), p=0.049; chronic benzodiazepines use 30 (36.1%) vs 6 (17.1%), p=0.050. PI-DRP: indication 10 (12%) vs 2 (5.7%) patients, p=0.506; effectivity 11 (13.3%) vs five (14.3), p=0.881; safety one (1.2%) vs four (11.4%), p=0.027; advice to nursing three (3.6%) vs two (5.7%), p=0.632; others 11 (13.3%) vs five (14.3%), p=0.881.ConclusionCCP–ACD group are older than CCP, and have worse results in functional status without differences in cognitive function.Although the number of chronic drugs prescribed between the two groups are similar, CCP–ACD have significantly less PIP and use less chronic benzodiazepines than CCP.The major pharmaceutical interventions have been those of safety in the CCP–ACD group.References and/or AcknowledgementsAll medical and nursing staff of Geriatric-Healthcare Centre.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2018-eahpconf.351</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Benzodiazepines ; Chronic illnesses ; Geriatrics ; Health care ; Patients ; Polypharmacy ; Section 4: Clinical pharmacy services</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A163-A163</ispartof><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535433/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535433/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Roig, S Ortonobes</creatorcontrib><creatorcontrib>Comas, G Puig</creatorcontrib><creatorcontrib>Marzo, MA Villarino</creatorcontrib><creatorcontrib>Monte, R Comet</creatorcontrib><creatorcontrib>Albors, P Miralles</creatorcontrib><creatorcontrib>Contel, A Perez</creatorcontrib><creatorcontrib>Molas, G</creatorcontrib><creatorcontrib>Gómez-Valent, M</creatorcontrib><title>4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions?</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundImpaired functionality, cognitive decline, comorbidity and polypharmacy in nonagenarians increase mortality risks associated with age. Polypharmacy (>4 chronic drugs) in elderly people is related to an increase in drug-related problems (DRP) and worse health outcomes due to potentially inappropriate prescriptions (PIP). To optimise medical care for chronic patients, our healthcare system stratifies chronic patients according to their grade of chronicity in chronic complex patients (CCP) or CCP with advance chronic disease (CCP-ACD).PurposeTo evaluate the differences related to functionality, cognition, polypharmacy and pharmacist interventions due to DRP (PI-DRP) regarding the grade of chronicity.Material and methodsWe included ≥90 years-old patients with polypharmacy discharged between January and June of 2017 from an Acute Geriatric Unit (81 beds) of a Geriatric Healthcare Centre. Registered variables: age, sex, grade of chronicity, Barthel Index and Pfeiffer Test before admission. Number of chronic drug/patient, number of PIP/patient and chronic benzodiazepines use before admission, and PI-DRP. Data are presented as median (Q1–Q3). We use Fisher’s exact test for qualitative and the Mann–Whitney U test and the Wilcoxon signed-rank test for quantitative data. Statistical analysis was performed with Stata 13.ResultsOne hundred and eighteen patients included: 83 CCP and 35 CCP-ACD. Differences between CCP and CCP-ACD: age 92 (90–94) vs 94 (91–95), p=0.029. Females 58 (69.9%) vs 20 (57.1%), p=0.205. Data at admission: Barthel Index 55 (40–80) vs 40 (20–60), p=0.010; Pfeiffer Test three (1–6) vs four (2–8), p=0.432. Chronic drugs/patient 10 (8–12) vs 10 (7–14), p=0.972. Average of PIP/patient 1.2 (±0.88) vs 0.86 (±0.85), p=0.049; chronic benzodiazepines use 30 (36.1%) vs 6 (17.1%), p=0.050. PI-DRP: indication 10 (12%) vs 2 (5.7%) patients, p=0.506; effectivity 11 (13.3%) vs five (14.3), p=0.881; safety one (1.2%) vs four (11.4%), p=0.027; advice to nursing three (3.6%) vs two (5.7%), p=0.632; others 11 (13.3%) vs five (14.3%), p=0.881.ConclusionCCP–ACD group are older than CCP, and have worse results in functional status without differences in cognitive function.Although the number of chronic drugs prescribed between the two groups are similar, CCP–ACD have significantly less PIP and use less chronic benzodiazepines than CCP.The major pharmaceutical interventions have been those of safety in the CCP–ACD group.References and/or AcknowledgementsAll medical and nursing staff of Geriatric-Healthcare Centre.No conflict of interest</description><subject>Benzodiazepines</subject><subject>Chronic illnesses</subject><subject>Geriatrics</subject><subject>Health care</subject><subject>Patients</subject><subject>Polypharmacy</subject><subject>Section 4: Clinical pharmacy services</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkV9LwzAUxYsoOOa-Q9Dnzvxp0sYHRYZOYaCgPoe0SdaMNalpO9mbL35RP4md-wM--XQv3HPOPfCLonMExwgRdqkXZV3KUMUYoizWsqwL78yYUHQUDTBM0phzlhwfdspOo1HT2BxSQjKeED6ITDJ5fokxQ9-fX9MglQbegKIM3tnCtmtgHXDeybl2MljpmitQSAc-NCh8VcuggeuqXAcgnQLtuv61q9DNe2Orw0q71nrX3JxFJ0YuGz3azWH0dn_3OnmIZ0_Tx8ntLM4x5ChWCmlFecZVghk0KtUpQ1wRlOrE5BhjjY0hCOEixSyHhkhJc8wNpIxmjHMyjK63uXWXV1oV_f8gl6IOtpJhLby04u_F2VLM_UqklNCEkD7gYhcQ_Hunm1YsfBdc31lgSnHKMv6PCiJICMrQRkW3qrxaHCogKDbwxB7expCJPTzRwyM_BNOTZQ</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Roig, S Ortonobes</creator><creator>Comas, G Puig</creator><creator>Marzo, MA Villarino</creator><creator>Monte, R Comet</creator><creator>Albors, P Miralles</creator><creator>Contel, A Perez</creator><creator>Molas, G</creator><creator>Gómez-Valent, M</creator><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20180301</creationdate><title>4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions?</title><author>Roig, S Ortonobes ; Comas, G Puig ; Marzo, MA Villarino ; Monte, R Comet ; Albors, P Miralles ; Contel, A Perez ; Molas, G ; Gómez-Valent, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2091-dd1ed5989d4260fd7e7619d317e4fb222e2ff3112c726b0f3aa5b29f056586993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Benzodiazepines</topic><topic>Chronic illnesses</topic><topic>Geriatrics</topic><topic>Health care</topic><topic>Patients</topic><topic>Polypharmacy</topic><topic>Section 4: Clinical pharmacy services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roig, S Ortonobes</creatorcontrib><creatorcontrib>Comas, G Puig</creatorcontrib><creatorcontrib>Marzo, MA Villarino</creatorcontrib><creatorcontrib>Monte, R Comet</creatorcontrib><creatorcontrib>Albors, P Miralles</creatorcontrib><creatorcontrib>Contel, A Perez</creatorcontrib><creatorcontrib>Molas, G</creatorcontrib><creatorcontrib>Gómez-Valent, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roig, S Ortonobes</au><au>Comas, G Puig</au><au>Marzo, MA Villarino</au><au>Monte, R Comet</au><au>Albors, P Miralles</au><au>Contel, A Perez</au><au>Molas, G</au><au>Gómez-Valent, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions?</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2018-03-01</date><risdate>2018</risdate><volume>25</volume><issue>Suppl 1</issue><spage>A163</spage><epage>A163</epage><pages>A163-A163</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundImpaired functionality, cognitive decline, comorbidity and polypharmacy in nonagenarians increase mortality risks associated with age. Polypharmacy (>4 chronic drugs) in elderly people is related to an increase in drug-related problems (DRP) and worse health outcomes due to potentially inappropriate prescriptions (PIP). To optimise medical care for chronic patients, our healthcare system stratifies chronic patients according to their grade of chronicity in chronic complex patients (CCP) or CCP with advance chronic disease (CCP-ACD).PurposeTo evaluate the differences related to functionality, cognition, polypharmacy and pharmacist interventions due to DRP (PI-DRP) regarding the grade of chronicity.Material and methodsWe included ≥90 years-old patients with polypharmacy discharged between January and June of 2017 from an Acute Geriatric Unit (81 beds) of a Geriatric Healthcare Centre. Registered variables: age, sex, grade of chronicity, Barthel Index and Pfeiffer Test before admission. Number of chronic drug/patient, number of PIP/patient and chronic benzodiazepines use before admission, and PI-DRP. Data are presented as median (Q1–Q3). We use Fisher’s exact test for qualitative and the Mann–Whitney U test and the Wilcoxon signed-rank test for quantitative data. Statistical analysis was performed with Stata 13.ResultsOne hundred and eighteen patients included: 83 CCP and 35 CCP-ACD. Differences between CCP and CCP-ACD: age 92 (90–94) vs 94 (91–95), p=0.029. Females 58 (69.9%) vs 20 (57.1%), p=0.205. Data at admission: Barthel Index 55 (40–80) vs 40 (20–60), p=0.010; Pfeiffer Test three (1–6) vs four (2–8), p=0.432. Chronic drugs/patient 10 (8–12) vs 10 (7–14), p=0.972. Average of PIP/patient 1.2 (±0.88) vs 0.86 (±0.85), p=0.049; chronic benzodiazepines use 30 (36.1%) vs 6 (17.1%), p=0.050. PI-DRP: indication 10 (12%) vs 2 (5.7%) patients, p=0.506; effectivity 11 (13.3%) vs five (14.3), p=0.881; safety one (1.2%) vs four (11.4%), p=0.027; advice to nursing three (3.6%) vs two (5.7%), p=0.632; others 11 (13.3%) vs five (14.3%), p=0.881.ConclusionCCP–ACD group are older than CCP, and have worse results in functional status without differences in cognitive function.Although the number of chronic drugs prescribed between the two groups are similar, CCP–ACD have significantly less PIP and use less chronic benzodiazepines than CCP.The major pharmaceutical interventions have been those of safety in the CCP–ACD group.References and/or AcknowledgementsAll medical and nursing staff of Geriatric-Healthcare Centre.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2018-eahpconf.351</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A163-A163 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535433 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Benzodiazepines Chronic illnesses Geriatrics Health care Patients Polypharmacy Section 4: Clinical pharmacy services |
title | 4CPS-261 Grade of chronicity in nonagenarians: can we compare number and type of drug interventions? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T11%3A53%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-261%E2%80%85Grade%20of%20chronicity%20in%20nonagenarians:%20can%20we%20compare%20number%20and%20type%20of%20drug%20interventions?&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Roig,%20S%20Ortonobes&rft.date=2018-03-01&rft.volume=25&rft.issue=Suppl%201&rft.spage=A163&rft.epage=A163&rft.pages=A163-A163&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2018-eahpconf.351&rft_dat=%3Cproquest_pubme%3E2552768933%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2010331813&rft_id=info:pmid/&rfr_iscdi=true |